GoodRx (NASDAQ:GDRX) Given New $4.50 Price Target at Citigroup

by · The Markets Daily

GoodRx (NASDAQ:GDRX – Get Free Report) had its target price cut by investment analysts at Citigroup from $5.00 to $4.50 in a research note issued to investors on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. Citigroup’s price target points to a potential upside of 62.16% from the stock’s previous close.

Other analysts have also recently issued reports about the company. Wall Street Zen cut GoodRx from a “buy” rating to a “hold” rating in a research report on Saturday, November 15th. JPMorgan Chase & Co. cut their price objective on GoodRx from $6.00 to $5.00 and set an “overweight” rating on the stock in a report on Tuesday, November 11th. Morgan Stanley cut their price objective on shares of GoodRx from $5.00 to $4.00 and set an “equal weight” rating on the stock in a research report on Thursday, December 18th. Weiss Ratings reiterated a “sell (d)” rating on shares of GoodRx in a research note on Tuesday, December 23rd. Finally, Barclays initiated coverage on GoodRx in a research note on Monday, December 8th. They issued an “underweight” rating and a $3.00 price target for the company. Five investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $4.91.

Check Out Our Latest Stock Report on GDRX

GoodRx Price Performance

Shares of GDRX stock traded down $0.02 during mid-day trading on Friday, hitting $2.78. 466,153 shares of the stock traded hands, compared to its average volume of 1,822,149. The company’s 50-day simple moving average is $2.85 and its 200-day simple moving average is $3.84. The firm has a market cap of $941.93 million, a price-to-earnings ratio of 30.83, a price-to-earnings-growth ratio of 1.06 and a beta of 1.45. GoodRx has a twelve month low of $2.61 and a twelve month high of $5.81. The company has a debt-to-equity ratio of 0.81, a quick ratio of 3.11 and a current ratio of 3.11.

GoodRx (NASDAQ:GDRX – Get Free Report) last posted its quarterly earnings data on Tuesday, November 4th. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.01). The firm had revenue of $196.03 million for the quarter, compared to analysts’ expectations of $195.17 million. GoodRx had a return on equity of 9.73% and a net margin of 3.97%.The company’s revenue for the quarter was up .4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.08 earnings per share. As a group, equities research analysts expect that GoodRx will post 0.13 earnings per share for the current year.

Insider Transactions at GoodRx

In other news, major shareholder Equity Vii L.P. Spectrum sold 23,771 shares of the firm’s stock in a transaction that occurred on Wednesday, October 15th. The shares were sold at an average price of $4.00, for a total transaction of $95,084.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 4.53% of the company’s stock.

Institutional Investors Weigh In On GoodRx

Hedge funds and other institutional investors have recently bought and sold shares of the business. Quarry LP purchased a new stake in GoodRx during the 3rd quarter valued at about $33,000. Cetera Investment Advisers bought a new stake in GoodRx in the second quarter valued at approximately $50,000. Boothbay Fund Management LLC purchased a new stake in shares of GoodRx during the third quarter valued at approximately $43,000. Shay Capital LLC bought a new position in shares of GoodRx in the third quarter worth approximately $47,000. Finally, Walled Lake Planning & Wealth Management LLC bought a new position in shares of GoodRx in the second quarter worth approximately $55,000. Institutional investors own 63.77% of the company’s stock.

About GoodRx

(Get Free Report)

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.

Further Reading